Icomb

Amlodipine and ramipril, the active ingredients in Icomb, are a calcium channel blocker and ACE inhibitor presented as a tablet for oral use. They treat hypertension in adult patients.

GNH USA supplies Icomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icomb is an antihypertensive medication that lowers elevated blood pressure through combined calcium‑channel blockade and angiotensin‑converting‑enzyme inhibition.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Secondary hypertension: assists in blood‑pressure control when hypertension is caused by another underlying condition. - Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction in hypertensive individuals.

Icomb may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness: especially after the first dose. - Flushing: transient warmth and redness of the skin. - Cough: dry, persistent cough associated with ACE inhibition. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Hyperkalemia: elevated blood potassium levels, particularly with concomitant potassium‑sparing agents. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.

Before initiating Icomb, clinicians should evaluate patient‑specific factors and monitor therapy. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing diuretics. - Hypersensitivity: discontinue if signs of angioedema or severe rash appear. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Icomb can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may cause renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may raise amlodipine concentrations. - Other antihypertensives (beta‑blockers, diuretics): additive blood‑pressure lowering effect. - Antidiabetic agents: enhanced glucose‑lowering effect, requiring dose adjustment. - Rifampicin: may reduce ramipril levels, diminishing efficacy.